Teva Pharmaceutical Industries (TEVA) Accumulated Expenses (2017 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Accumulated Expenses for 10 consecutive years, with $488.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Expenses rose 1.46% year-over-year to $488.0 million; the trailing twelve-month figure through Jun 2026 stood at $488.0 million (up 1.46% YoY), and the FY2025 full-year result was $739.0 million, up 18.43% from the prior year.
• Accumulated Expenses eased to $488.0 million in Q2 2026 per TEVA's latest filing, from $555.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $739.0 million in Q4 2025 and bottomed at $432.0 million in Q1 2023.
• Historically, Accumulated Expenses has averaged $531.1 million across 5 years, with a median of $494.0 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses declined 10.63% in 2022, then rose 18.43% in 2025.
• Over 5 years, Accumulated Expenses stood at $566.0 million in 2022, then rose by 7.95% to $611.0 million in 2023, then increased by 2.13% to $624.0 million in 2024, then grew by 18.43% to $739.0 million in 2025, then slumped by 33.96% to $488.0 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $488.0 million, $555.0 million, and $739.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.